A Phase 2 interventional study of Allogeneic stem cell transplantation and Ruxolitinib continuous therapy in Bone Marrow Fibrosis, sponsored by Universitätsklinikum Hamburg-Eppendorf. Active, not recruiting at 14 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Primary Myelofibrosis with a site in Germany — 15 open to participants now, 29 under way, 9 of them phase 3. Primary Myelofibrosis · Germany.
Among the 75 studies in Primary Myelofibrosis with a site in Germany, this one is the 42nd largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 2, reaches primary completion later than 4 of the 28 other live ones, and was the 35th registered.
626 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →15 of the 75 studies in Primary Myelofibrosis with a site in Germany are open now. Recruiting first, the newest first:
Takeda · Sites in Germany, United States, Argentina and 28 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 21 more countries
Ages 18+
Incyte Corporation · Sites in Germany, United States, Australia and 8 more countries
Ages 18+
iOMEDICO AG · Sites in Germany
Ages 18+
Incyte Corporation · Sites in Germany, United States, Australia and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 33 · Phase 3 24 · Phase 4 1
First in 1999; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 116 across the 70 interventional studies, 617 across the 5 observational. Of the 45 that completed or were terminated, 28 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 75 have an industry lead sponsor. The 10 most frequent:
Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
Universitätsklinikum Hamburg-Eppendorf has 2 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Primary Myelofibrosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT01761968ItalfarmacoLong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | 2026-12 |
| NCT03441113GlaxoSmithKlineExtended Access of Momelotinib in Adults With Myelofibrosis | 2026-12-11 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT06517875GlaxoSmithKlineStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | 2027-03-16 |
Add all 7 to your calendar (.ics) → With an account.
Among the 75 studies in Primary Myelofibrosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.
This study is a multicenter, prospective phase II-study compares efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.
In this study will further assess and compare the safety and efficacy of study treatments/ induction therapy in both study arms on spleen reduction, improvement of constitutional symptoms, QOL, toxicity, fibrosis regression, development of GvHD as well as chimerism, engraftment, relapse incidence, disease related mortality, outcome and overall survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe renal, hepatic, pulmonary or cardiac disease, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
Procedure: Allogeneic stem cell transplantation
Treatment with Ruxolitinib continuous therapy
Drug: Ruxolitinib continuous therapy
Also known as: Jakavi
Event free survival
Compare to event free survival of patients at 3 years after allogeneic SCT and in Ruxolitinib continuous therapy in patients without a suitable donor
Time frame: 3 years
Spleen reduction
Ultrasound measurement Spleen size, reduction of Spleen size after 3 months Ruxolitinib induction therapy
Time frame: 3 months
Improvement of constitutional symptoms
Improvement of constitutional symptoms (Loose of weight and night sweat) after 3 months Ruxolitinib induction therapy, questionnaire, medical history
Time frame: 3 months
Improvement of bone marrow fibrosis
bone marrow histology, Improvement of bone marrow fibrosis after 3 months of Ruxolitinib induction therapy
Time frame: 3 months
Acute graft-versus-host disease
Incidence of acute graft-versus-host disease on Day +100 after allogeneic SCT according to the Glucksberg scale revised by Przepiorka
Time frame: Day +100 after allogeneic SCT
Chronic graft-versus-host disease
Incidence of chronic graft-versus-host disease according to the NIH consensus criteria of Filipovich et al. at 1, 2 and 3 years after allogeneic SCT
Time frame: 1, 2 and 3 years after allogeneic SCT
Toxicity of Ruxolitinib
Toxicity of Ruxolitinib scored according to NCI CTCAE, Version 4.0
Time frame: till 3 years
Toxicity of conditioning therapy
Toxicity of conditioning therapy scored according to NCI CTCAE, Version 4.0
Time frame: till 3 years
Relapse
Cumulative incidence of relapse at 3 years after allogeneic SCT
Time frame: 3 years
Disease-related mortality
Disease-related mortality at 3 years after allogeneic SCT and Ruxolitinib continuous therapies
Time frame: 3 years
Non-relapsed mortality
Non-relapsed mortality at 1 and 3 years after allogeneic SCT and Ruxolitinib continuous therapy
Time frame: 1 and 3 years
Discontinuation rate
Discontinuation rate at 3 years after Ruxolitinib continuous therapy (End of study)
Time frame: 3 years
Evaluation of Sorror Risk Score
Evaluation of Sorror Risk Score on outcome after allogeneic SCT
Time frame: at baseline
Chimerism on relapse
Chimerism Analyse, Impact of chimerism on relapse incidence after allogeneic SCT
Time frame: 30d, 100d, 180 d, 1 year, 2 years and 3 years
Bone marrow fibrosis regression
bone marrow histology, Evaluation of bone marrow fibrosis regression after allogeneic SCT at 30d, 100d, 1 year, and 3 years
Time frame: 30d, 100d, 1 year, and 3 years
Bone marrow fibrosis regression
bone marrow histology, Evaluation of bone marrow fibrosis regression after Ruxolitinib continuous therapy at 30d, 100d, 1 year and 3 years
Time frame: 30d, 100d, 1 year and 3 years
Evaluation of QOL (FACT-BMT)
Questionnaire, Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years
Time frame: baseline, at transplantation, +180d, +1 year, +2 years and +3 years
Evaluation of QOL (MPN-SAF-TSS)
Questionaire, Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years
Time frame: baseline, at transplantation, +180d, +1 year, +2 years and +3 years
Evaluation of QOL (FACT-BMT)
Questionnaire, Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years
Time frame: baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years
Evaluation of QOL (MPN-SAF-TSS)
Questionnaire, Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years
Time frame: baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years
Overall Survival
Overall survival at 3 years after allogeneic SCT compared to Ruxolitinib continuous therapy in patients without a suit-able donor
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2016 to primary completion in Oct 2024, 93 months.
Of 68 non-industry phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's 93 months is above that.
Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitätsklinikum Hamburg-Eppendorf →